TAIWANESE HEALTH AND RESEARCH DELEGATION VISIT PARATUS CLINICAL TRIAL SITE IN CANBERRA Visit fosters greater collaboration and experience of clinical trial execution in public and private health settings best practice
With
Matt Clacy,
Founder & Chief Commercial Officer
Paratus Clinical
Dr Amber Leah,
Principal Investigator & Medical Director
Paratus Clinical
Professor Chun-Jen Huang,
Dean of Office of Human Research
Taipei Medical University & Taipei Municipal Wanfang Hospital
Taiwan
Professor Pin-Kuei Fu,
Director, Clinical Research Center
Taichung Veterans General Hospital
Taiwan
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Canberra | September 2025
In late August 2025, a Taiwanese delegation comprising government officials from the Taiwanese FDA, various governmental groups, and physicians and researchers from across Taiwan, visited Paratus Clinical’s trial site in Canberra. Their objective was to explore both the differences and similarities between the clinical research ecosystems of Taiwan and Australia.
Throughout the discussions, the delegation learned about the processes involved in initiating research, the regulatory hurdles that must be navigated, and the practicalities of conducting clinical trials in both public and private sectors.
Paratus Clinical specialises in a range of clinical trials, from Phase I to Phase III, including vaccine studies and treatments across primary care areas such as asthma, diabetes, and cardiometabolic health, as well as outpatient specialties like dermatology and oncology.
The conversations also addressed the distinctions between inpatient and outpatient care, focusing on startup timelines, regulatory requirements, and patient recruitment strategies. Notably, the delegation found a reassuring number of similarities in clinical practice between the two countries.
Matt Clacy, recognised the potential benefit of fostering greater collaboration between public and private sectors in Australia, a practice that is more prevalent in Taiwan and advantageous for patient care and the healthcare system overall.
Source: Written by AUDIENCED
You Might also like
-
The focus on reducing instances of birth-trauma through trauma-informed care
Leading into Birth Trauma Week 2026, in an interview with Australian Health Journal, Dr Nisha Khot, President of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), highlighted the growing focus on reducing birth trauma through trauma-informed, multidisciplinary care.
-
Chiropractors commence Spinal Health Month with research in mental health
The Australian Federal 2026–27 Budget included several significant announcements relating to allied health services for veterans, largely tied to the Government’s response to recommendations from the Royal Commission into Defence and Veteran Suicide.
-
Sovereign capability uplifted
Skilled labour, in particular skilled in the manufacture of MTP products, namely competency in Good Manufacturing Practice (GMP), was identified as one of the key priorities, according to Jarrod Belcher, Director of the REDI Program at MTPConnect. Through a competitive process, MTPConnect selected additional industry training providers to deliver new programs addressing key skills gaps in the sector workforce.
Launched in September 2022, one of these programs is GMP Uplift developed by the Centre for Biopharmaceutical Excellence (CBE). CBE bring experience across large and small Biologics, Pharmaceuticals and Regenerative Medicine companies, both in consulting and GMP related enterprise training. CBE staff also have extensive experience in GMP operations, compliance, auditing and QMS design, a wide industry network for guest lecturers and readily available case studies.